Enrichment of variations in KIR3DL1/s1 and KIR2DL2/L3 among H1N1/09 ICU patients: An exploratory study

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  La, David ^a   Czarnecki, Chris ^a   El Gabalawy, Hani ^b   Kumar, Anand ^b   Meyers, Adrienne F A ^a,b   Bastien, Nathalie ^a   Simonsen, J Neil ^a   Plummer, Francis A ^a,b   Luo, Ma ^a,b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B ANTIGEN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KIR2DL2 PROTEIN, HUMAN; KIR2DL3 PROTEIN, HUMAN; KIR3DL1 PROTEIN, HUMAN; PRIMER DNA;

2009 H1N1 INFLUENZA; ABORIGINE; ALLOTYPE; AMERICAN INDIAN; APACHE; ARTICLE; CANADA; CAUCASIAN; CONTROLLED STUDY; DISEASE SEVERITY; EXPLORATORY RESEARCH; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HLA B BW4 GENE; HLA C C1 GENE; HUMAN; INTENSIVE CARE; KIR3DL1 GENE; KIR3DL2 GENE; KIR3DL3 GENE; KIR3DS1 GENE; MAJOR CLINICAL STUDY; MORTALITY; NATURAL KILLER CELL; GENETICS; INFLUENZA; INFLUENZA VIRUS A H1N1; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; METABOLISM; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROBABILITY; VIROLOGY;

INFLUENZA A VIRUS;

APACHE; BASE SEQUENCE; DNA PRIMERS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INTENSIVE CARE UNITS; POLYMERASE CHAIN REACTION; PROBABILITY; RECEPTORS, KIR2DL2; RECEPTORS, KIR2DL3; RECEPTORS, KIR3DL1;

EID: 84555218926     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029200     Document Type: Article

References (51)

1. Presanis AM, Angelis DD, Hagy A, Reed C, et al. The New York City Swine Flu Investigation Team (2009) The severity of pandemic H1N1 influenza in the United States, from April to July 2009: A Bayesian analysis. PLoS Med 6: e1000207.
2. Paine S, Mercer GN, Kelly PM, Bandaranayake D, Baker MG, et al. (2010) Transmissibility of 2009 pandemic influenza A(H1N1) in New Zealand: Effective reproduction number and influence of age, ethnicity and importations. Euro Surveill 15: 19591.
3. World Health Organization (WHO) (2009) Pandemic (H1N1) 2009- update 76. Available: http://www.who.int/csr/don/2009_11_27a/en/index.html. Accessed 2010 Oct 19.
4. World Health Organization (WHO) (2010) Pandemic (H1N1) 2009- update 112. Available: http://www.who.int/csr/don/2010_08_06/en/index.html. Accessed 2010 Oct 19.
5. Turner SJ, Doherty PC, Kelso A, (2010) Q&A: H1N1 pandemic influenza-what's new? BMC Biol 8: 130 10.1186/1741-7007-8-130.
6. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, et al. (2010) Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328: 357-360 10.1126/science.1186430.
7. La Ruche G, Tarantola A, Barboza P, Vaillant L, Gueguen J, et al. (2009) The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific. Euro Surveill 14: pii = 19366.
8. Dee S, Jayathissa S, (2010) Clinical and epidemiological characteristics of the hospitalised patients due to pandemic H1N1 2009 viral infection: Experience at Hutt Hospital, New Zealand. N Z Med J 123: 45-53.
9. Wada K, Nishiura H, Kawana A, (2010) An epidemiological analysis of severe cases of the influenza A (H1N1) 2009 virus infection in Japan. Influenza Other Respi Viruses 4: 179-186.
10. Chitnis AS, Truelove SA, Druckenmiller JK, Heffernan RT, Davis JP, (2010) Epidemiologic and clinical features among patients hospitalized in Wisconsin with 2009 H1N1 influenza A virus infections, April to August 2009. WMJ 109: 201-208.
11. Zarychanski R, Stuart TL, Kumar A, Doucette S, Elliott L, et al. (2010) Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 182: 257-264 10.1503/cmaj.091884.
12. Denney L, Aitken C, Li CK, Wilson-Davies E, Kok WL, et al. (2010) Reduction of natural killer but not effector CD8 T lymphocytes in three consecutive cases of severe/lethal H1N1/09 influenza A virus infection. PLoS One 5: 1-9.
13. Liu B, Mori I, Hossain MJ, Dong L, Takeda K, et al. (2004) Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. J Gen Virol 85: 423-428.
14. Fauci AS, Mavilio D, Kottilil S, (2005) NK cells in HIV infection: Paradigm for protection or targets for ambush. Nature Immunology Reviews 5: 835-843.
15. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S, (2008) Functions of natural killer cells. Nat Immunol 9: 503-510 10.1038/ni1582.
16. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, et al. (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49 10.1126/science.1198687.
17. Hoglund P, Brodin P, (2010) Current perspectives of natural killer cell education by MHC class I molecules. Nat Rev Immunol 10: 724-734 10.1038/nri2835.
18. Lanier LL, (2005) NK cell recognition. Annu Rev Immunol 23: 225-274.
19. Carrington M, Norman P, (2003) The KIR gene cluster. Bethesda, MD: National Library of Medicine (US). 48 p. Available: http://www.ncbi.nlm.nih.gov/books/NBK10134/. Accessed 2010 Oct 19.
20. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P, (1995) The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 181: 1133-1144.
21. Gillespie GM, Bashirova A, Dong T, McVicar DW, Rowland-Jones SL, et al. (2007) Lack of KIR3DS1 binding to MHC class I Bw4 tetramers in complex with CD8+ T cell epitopes. AIDS Res Hum Retroviruses 23: 451-455 10.1089/aid.2006.0165.
22. Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL, (1993) HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci U S A 90: 12000-12004.
23. Wagtmann N, Rajagopalan S, Winter CC, Peruzzi M, Long EO, (1995) Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity 3: 801-809.
24. Kulkarni S, Martin MP, Carrington M, (2008) The yin and yang of HLA and KIR in human disease. Semin Immunol 20: 343-352 10.1016/j.smim.2008.06.003.
25. Khakoo SI, Carrington M, (2006) KIR and disease: A model system or system of models? Immunol Rev 214: 186-201 10.1111/j.1600-065X.2006.00459.x.
26. Jamil KM, Khakoo SI, (2011) KIR/HLA interactions and pathogen immunity. J Biomed Biotechnol 2011: 298348 10.1155/2011/298348.
27. Lutz CT, Smith KD, Greazel NS, Mace BE, Jensen DA, et al. (1994) Bw4-reactive and Bw6-reactive antibodies recognize multiple distinct HLA structures that partially overlap in the alpha-1 helix. J Immunol 153: 4099-4110.
28. Rempel JD, Hawkins K, Lande E, Nickerson P, (2011) The potential influence of KIR cluster profiles on disease patterns of Canadian aboriginals and other indigenous peoples of the Americas. Eur J Hum Genet 19: 1276-1280 10.1038/ejhg.2011.114.
29. Webster P, (2009) Federal policies fuel spread of swine flu, experts say. CMAJ 181: E90-91 10.1503/cmaj.091355.
30. Embree J, (2010) Pandemic 2009 (A)H1N1 influenza (swine flu)- the Manitoba experience. Biochem Cell Biol 88: 589-593 10.1139/o10-025.
31. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR, (2011) Allele frequency net: A database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 39: D913-919 10.1093/nar/gkq1128.
32. Gendzekhadze K, Norman PJ, Abi-Rached L, Layrisse Z, Parham P, (2006) High KIR diversity in Amerindians is maintained using few gene-content haplotypes. Immunogenetics 58: 474-480 10.1007/s00251-006-0108-3.
33. Carrington M, Gao X, Norman P, (2004) KIR gene allele frequencies in populations from USA (African American) USA (European) and England. Hum Immun 65: 1191-1191.
34. Norman PJ, Abi-Rached L, Gendzekhadze K, Korbel D, Gleimer M, et al. (2007) Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nat Genet 39: 1092-1099 10.1038/ng2111.
35. Knaus WA, Draper EA, Wagner DP, Zimmerman JE, (1985) APACHE II: A severity of disease classification system. Crit Care Med 13: 818-829.
36. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, et al. (2008) Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 180: 3969-3979.
37. Kaufman MA, Duke GJ, McGain F, French C, Aboltins C, et al. (2009) Life-threatening respiratory failure from H1N1 influenza 09 (human swine influenza). Med J Aust 191: 154-156.
38. Echevarria-Zuno S, Mejia-Arangure JM, Mar-Obeso AJ, Grajales-Muniz C, Robles-Perez E, et al. (2009) Infection and death from influenza A H1N1 virus in Mexico: A retrospective analysis. Lancet 374: 2072-2079 10.1016/S0140-6736(09)61638-X.
39. O'Riordan S, Barton M, Yau Y, Read SE, Allen U, et al. (2010) Risk factors and outcomes among children admitted to hospital with pandemic H1N1 influenza. CMAJ 182: 39-44 10.1503/cmaj.091724.
40. Carr WH, Pando MJ, Parham P, (2005) KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol 175: 5222-5229.
41. Gardiner CM, Guethlein LA, Shilling HG, Pando M, Carr WH, et al. (2001) Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol 166: 2992-3001.
42. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, et al. (2006) Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 203: 633-645 10.1084/jem.20051884.
43. Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, et al. (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12: 205-216.
44. Reinders J, Rozemuller EH, Otten HG, Houben AJ, Dormoy A, et al. (2005) Identification of HLA-A*0111N: A synonymous substitution, introducing an alternative splice site in exon 3, silenced the expression of an HLA-A allele. Hum Immunol 66: 912-920 10.1016/j.humimm.2005.06.010.
45. Hardie RA, Czarnecki C, Ball TB, Plummer FA, Luo M, (2010) Identification of four novel KIR2DL2 alleles and two novel KIR2DL3 alleles in an East African population. Hum Immunol 71: 1251-1254 10.1016/j.humimm.2010.09.013.
46. Luo M, Embree J, Ramdahin S, Ndinya-Achola J, Njenga S, et al. (2002) HLA-A and HLA-B in Kenya, Africa: Allele frequencies and identification of HLA-B*1567 and HLA-B*4426. Tissue Antigens 59: 370-380.
47. Robinson J, Malik A, Parham P, Bodmer JG, Marsh SGE, (2000) IMGT/HLA- a sequence database for the human major histocompatibility complex. Tissue Antigens 55: 280-287.
48. Robinson J, Waller MJ, Stoehr P, Marsh SGE, (2005) IPD- the immuno polymorphism database. Nucleic Acids Research 331: D523-D526.
49. Robinson J, Mistry K, McWilliam H, Lopez R, Parham P, et al. (2011) The IMGT/HLA database. Nucleic Acids Research 39: D1171-D1176.
50. Carlson JM, Heckerman D, Shani G, (2009) Estimating false discovery rates for contingency tables (MSR-TR-2009-53). Available: http://research.microsoft.com/en-us/um/redmond/projects/MSCompBio/FalseDiscoveryRate. Accessed 2010 Oct 19.
51. Lowry R, (2011) VassarStats: Website for statistical computation. Available: http://faculty.vassar.edu/lowry/odds2x2.html. Accessed 2011 Jun 22.